Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Mary Weiser-Evans and Katharina Hopp.

 
Connection Strength
 
 
 
0.491
 
  1. Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki M, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA, Hopp K. CD8+ T cells modulate autosomal dominant polycystic kidney disease progression. Kidney Int. 2018 12; 94(6):1127-1140.
    View in: PubMed
    Score: 0.163
  2. Kleczko EK, Poczobutt JM, Navarro AC, Laskowski J, Johnson AM, Korpela SP, Gurule NJ, Heasley LE, Hopp K, Weiser-Evans MCM, Gottlin EB, Bushey RT, Campa MJ, Patz EF, Thurman JM, Nemenoff RA. Upregulation of complement proteins in lung cancer cells mediates tumor progression. Front Oncol. 2022; 12:1045690.
    View in: PubMed
    Score: 0.055
  3. Montford JR, Bauer C, Rahkola J, Reisz JA, Floyd D, Hopp K, Soranno DE, Klawitter J, Weiser-Evans MCM, Nemenoff R, Faubel S, Furgeson SB. 15-Lipoxygenase worsens renal fibrosis, inflammation, and metabolism in a murine model of ureteral obstruction. Am J Physiol Renal Physiol. 2022 01 01; 322(1):F105-F119.
    View in: PubMed
    Score: 0.051
  4. Johnson AM, Boland JM, Wrobel J, Klezcko EK, Weiser-Evans M, Hopp K, Heasley L, Clambey ET, Jordan K, Nemenoff RA, Schenk EL. Cancer Cell-Specific Major Histocompatibility Complex II Expression as a Determinant of the Immune Infiltrate Organization and Function in the NSCLC Tumor Microenvironment. J Thorac Oncol. 2021 10; 16(10):1694-1704.
    View in: PubMed
    Score: 0.049
  5. Johnson AM, Bullock BL, Neuwelt AJ, Poczobutt JM, Kaspar RE, Li HY, Kwak JW, Hopp K, Weiser-Evans MCM, Heasley LE, Schenk EL, Clambey ET, Nemenoff RA. Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma. J Immunol. 2020 04 15; 204(8):2295-2307.
    View in: PubMed
    Score: 0.045
  6. Holditch SJ, Brown CN, Atwood DJ, Pokhrel D, Brown SE, Lombardi AM, Nguyen KN, Hill RC, Lanaspa M, Hopp K, Weiser-Evans MCM, Edelstein CL. The consequences of increased 4E-BP1 in polycystic kidney disease. Hum Mol Genet. 2019 12 15; 28(24):4132-4147.
    View in: PubMed
    Score: 0.044
  7. Bullock BL, Kimball AK, Poczobutt JM, Neuwelt AJ, Li HY, Johnson AM, Kwak JW, Kleczko EK, Kaspar RE, Wagner EK, Hopp K, Schenk EL, Weiser-Evans MC, Clambey ET, Nemenoff RA. Tumor-intrinsic response to IFN? shapes the tumor microenvironment and anti-PD-1 response in NSCLC. Life Sci Alliance. 2019 06; 2(3).
    View in: PubMed
    Score: 0.043
  8. Montford JR, Bauer C, Dobrinskikh E, Hopp K, Levi M, Weiser-Evans M, Nemenoff R, Furgeson SB. Inhibition of 5-lipoxygenase decreases renal fibrosis and progression of chronic kidney disease. Am J Physiol Renal Physiol. 2019 04 01; 316(4):F732-F742.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)